IL159898A0 - Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide - Google Patents

Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide

Info

Publication number
IL159898A0
IL159898A0 IL15989802A IL15989802A IL159898A0 IL 159898 A0 IL159898 A0 IL 159898A0 IL 15989802 A IL15989802 A IL 15989802A IL 15989802 A IL15989802 A IL 15989802A IL 159898 A0 IL159898 A0 IL 159898A0
Authority
IL
Israel
Prior art keywords
mammals
nitric oxide
pulmonary disease
disease states
treating pulmonary
Prior art date
Application number
IL15989802A
Other languages
English (en)
Original Assignee
Cellular Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellular Sciences Inc filed Critical Cellular Sciences Inc
Publication of IL159898A0 publication Critical patent/IL159898A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15989802A 2001-08-21 2002-08-15 Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide IL159898A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31387201P 2001-08-21 2001-08-21
PCT/US2002/026060 WO2003017996A1 (en) 2001-08-21 2002-08-15 Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide

Publications (1)

Publication Number Publication Date
IL159898A0 true IL159898A0 (en) 2004-06-20

Family

ID=23217517

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15989802A IL159898A0 (en) 2001-08-21 2002-08-15 Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide

Country Status (8)

Country Link
US (1) US6689810B2 (de)
EP (1) EP1427402A4 (de)
JP (1) JP2005501106A (de)
AU (1) AU2002329762B2 (de)
CA (1) CA2457983C (de)
IL (1) IL159898A0 (de)
MX (1) MXPA04000993A (de)
WO (1) WO2003017996A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070086954A1 (en) * 1998-11-23 2007-04-19 Miller Christopher C Method and apparatus for treatment of respiratory infections by nitric oxide inhalation
US9486429B2 (en) * 1999-06-01 2016-11-08 Vanderbilt University Therapeutic methods employing nitric oxide precursors
US6346382B1 (en) * 1999-06-01 2002-02-12 Vanderbilt University Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto
JP2003048831A (ja) * 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
US20030105162A1 (en) * 2001-08-21 2003-06-05 Celluar Sciences, Inc. Method for treating bronchial constriction and bronchospasm
US8076373B2 (en) * 2001-09-11 2011-12-13 North Cell Pharmacetical Method for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite
US20040220265A1 (en) * 2002-07-25 2004-11-04 Celluar Sciences, Inc. Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
US20080213403A1 (en) * 2002-07-25 2008-09-04 Alain Martin Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
WO2004028529A1 (en) * 2002-09-24 2004-04-08 Suntory Limited Composition with effects of decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person
US9138707B2 (en) 2002-12-10 2015-09-22 Sy Kimball Portable, nitric oxide generator
CA2413834A1 (en) * 2002-12-10 2004-06-10 1017975 Alberta Limited Nitric oxide gas generator
JP4522075B2 (ja) * 2003-10-29 2010-08-11 サントリーホールディングス株式会社 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物
WO2005067986A1 (en) 2004-01-07 2005-07-28 Noxilizer, Inc. Sterilization system and device
US8017074B2 (en) 2004-01-07 2011-09-13 Noxilizer, Inc. Sterilization system and device
EP1737482A4 (de) * 2004-03-01 2010-09-15 Lumen Therapeutics Llc Zusammensetzungen und verfahren zur behandlung von krankheiten
US20080008771A1 (en) * 2004-05-27 2008-01-10 Children's Hospital Medical Center Nitric Oxide Dioxygenase Inhibitors
JP2006083136A (ja) * 2004-09-17 2006-03-30 Suntory Ltd ストレスに起因する脳機能の低下およびそれに伴う症状あるいは疾患の予防又は改善作用を有する組成物
CA2589995C (en) * 2004-12-17 2016-01-05 Alan B. Cash Oxaloacetate, oxaloacetic acid, and oxaloacetate salts for treating cancer
JP5967855B2 (ja) * 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
JP5697293B2 (ja) * 2005-06-30 2015-04-08 サントリーホールディングス株式会社 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物
US20090018091A1 (en) 2005-08-02 2009-01-15 Nitromed, Inc. Nitric Oxide Enhancing Antimicrobial Compounds, Compositions and Methods of Use
US20090169646A1 (en) * 2006-02-22 2009-07-02 Puricore, Inc. Methods of treating cystic fibrosis
AU2007243765A1 (en) 2006-03-29 2007-11-08 Nicox S.A. Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
US8114907B2 (en) * 2007-08-08 2012-02-14 Cellular Sciences Inc Method for treating a pulmonary disease state in mammals by up regulating indigenous in vivo levels of inflammatory agents in mammalian cells
US9675569B2 (en) * 2007-08-08 2017-06-13 Alain Martin Method for treating a pulmonary disease state in mammals by up regulating indigenous in vivo levels of inflammatory agents in mammalian cells
US8211943B2 (en) * 2007-08-08 2012-07-03 Alain Martin Method for treating a pulmonary disease state in mammals by up regulating indigenous in vivo levels of inflammatory agents in mammalian cells
KR20170005155A (ko) * 2008-01-31 2017-01-11 반더빌트유니버시티 폐의 용태에 따른 치료 방법
CN102369006A (zh) * 2008-01-31 2012-03-07 范德比尔特大学 治疗冠状动脉和动脉的动脉瘤性蛛网膜下腔出血的方法和组合物
WO2010017633A1 (en) * 2008-08-13 2010-02-18 Chris Miller Use of nitric oxide
EP2362810A4 (de) 2008-09-22 2013-09-11 Geno Llc Umwandlung von stickstoffdioxid (no2) in stickstoffmonoxid (no)
EP2361099B1 (de) 2009-02-23 2012-09-12 Noxilizer, Inc. Verfahren zur gassterilisation
US9592211B2 (en) 2012-09-19 2017-03-14 Grespo Ab Compositions for improvement of brain function
US10517817B2 (en) 2013-05-09 2019-12-31 Syk Technologies, Llc Deep topical systemic nitric oxide therapy apparatus and method
EP3009839B1 (de) * 2013-06-14 2018-11-28 Seoul National University R&DB Foundation Verfahren zur erkennung von hypoxie oder zur diagnose von hypoxie-vermittelten erkrankungen
EP3936145A1 (de) * 2014-07-31 2022-01-12 The University Of Western Australia Verfahren zur identifizierung von immuntherapie-arzneimittel-kombinationen unter verwendung eines netzwerkansatzes
US20200237815A1 (en) * 2017-02-24 2020-07-30 Alain Martin Methods for treatment of lung damage and for inhibition of lung fibrosis
US11311505B2 (en) * 2017-02-24 2022-04-26 Cellular Sciences, Inc. Synergistic compositions to stimulate the synthesis of human lung and sinus surfactants to decrease coughing, increase FEV-1/FVC ratios, decrease lung fibrosis, by increasing apoptosis of myofibroblasts
EP4011372A4 (de) * 2019-08-06 2023-08-30 Lianyungang Jinkang Hexin Pharmaceutical Co. Ltd. Pharmazeutische zusammensetzung zur behandlung von afrikanischem schweinefieber und deren verwendung

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158883A (en) * 1989-09-13 1992-10-27 Cornell Research Foundation, Inc. Method of using aminoarginine to block nitric oxide formation in vitro
EP0441119A3 (en) * 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
US5147854A (en) * 1990-05-22 1992-09-15 Hoffmann-La Roche Inc. Tgf-b compositions and method
US5296370A (en) * 1990-10-04 1994-03-22 Rutgers, The State University Repair medium for the resuscitation of injured cells
US5891459A (en) * 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
US5798388A (en) * 1996-09-06 1998-08-25 Cellular Sciences, Inc. Method and composition for treating mammalian diseases caused by inflammatory response
CA2205112C (en) * 1995-09-19 2008-11-18 Cellular Sciences, Inc. Method and composition for treating mammalian diseases caused by inflammatory response

Also Published As

Publication number Publication date
EP1427402A1 (de) 2004-06-16
AU2002329762B2 (en) 2007-03-01
US20030040542A1 (en) 2003-02-27
CA2457983A1 (en) 2003-03-06
EP1427402A4 (de) 2007-12-05
US6689810B2 (en) 2004-02-10
CA2457983C (en) 2011-09-06
JP2005501106A (ja) 2005-01-13
MXPA04000993A (es) 2004-04-20
WO2003017996A1 (en) 2003-03-06

Similar Documents

Publication Publication Date Title
IL159898A0 (en) Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
EP1416961A4 (de) Zusammensetzung und verfahren zur behandlung von krankheiten
ZA200700904B (en) Method of treating sjögren's syndrome
IL157161A0 (en) Methods for treating disease states comprising administration of low levels of antibodies
HK1158493A1 (en) Hair treatment agent composition and method for production thereof
GB2393202B (en) Methods of well treatment
EP1450816A4 (de) Verfahren zur behandlung von störungen im zusammenhang mit erhöhter cholesterinkonzentration
AU5939901A (en) Methods of treating vascular diseases characterized by nitric oxide insufficiency
EP1667730A4 (de) Zusammensetzungen und verfahren zur behandlung von entzündlicher lungenerkrankung
EP1642592A4 (de) Mittel zur behandlung von sarcoidose und behandlungsverfahren dafür
EP1680145A4 (de) Verfahren und zusammensetzungen zur behandlung von neurologischen erkrankungen
EP1347051A4 (de) Verfahren zur untersuchung einer allergischen krankheit
PL368935A1 (en) Methods of treating pulmonary disease
EP1425021A4 (de) Physiologisches verfahren zur verbesserung der sehkraft
EP1450820A4 (de) Verfahren zur behandlung oder prävention von entzündlichen erkrankungen
EP1660116A4 (de) Verfahren zur behandlung von virusinfektionen
IL150963A0 (en) Method and compositions for treating an inflammatory disease
EP1389105A4 (de) Behandlungsverfahren
GB0112216D0 (en) Method of treatment
EP1284289A4 (de) Verfahren zur prüfung von allergien
EP1427429A4 (de) Zusammensetzungen und verfahren zur behandlung von patienten mit hyperglykämie
EP1681988A4 (de) Verfahren zur diagnose und behandlung von lungenerkrankungen
EP1637162A4 (de) Medizinische zusammensetzung zur prävention oder behandlung von immunologischen erkrankungen vom th1 typ
GB0118892D0 (en) Method of treatment
AU2002338894A1 (en) Methods and compositions for treating respiratory mucin production associated disease conditions